Loading...
•
Dec 28, 2019
TransMedics Q4 2019 Earnings Report
TransMedics reported financial results for the fourth quarter and year ended December 28, 2019.
Key Takeaways
TransMedics' net revenue for the fourth quarter of 2019 was $6.1 million, a 71% increase compared to the fourth quarter of 2018. Gross margin for the fourth quarter of 2019 was 62% as compared to 42% in the fourth quarter of 2018. Net loss for the fourth quarter of 2019 was $9.2 million compared to $7.6 million in the fourth quarter of 2018.
Net revenue of $6.1 million in the fourth quarter of 2019, representing 71% growth compared to the fourth quarter of 2018.
OCS Heart FDA Panel scheduled for April 16, 2020.
Initiated the OCS Heart DCD program enabling patients access to a broader pool of donor hearts.
Gross margin for the fourth quarter of 2019 was 62% as compared to 42% in the fourth quarter of 2018.
Forward Guidance
TransMedics expects net revenue for the full-year 2020 to be in the range of $40 million to $43 million, which represents 69% to 82% growth compared to the company’s prior year net revenue.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...